Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL) Share Price

Price 0.20p on 27-05-2026 at 18:35:12
Change 0.005p 2.56%
Buy 0.20p
Sell 0.19p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 150,000.00 at 0.20p
Day's Volume: 61,515,762
Last Close: 0.20p
Open: 0.195p
ISIN: GB00BLH13C52
Day's Range 0.20p - 0.20p
52wk Range: 0.19p - 0.80p
Market Capitalisation: £1.49m
VWAP: 0.201097p
Shares in Issue: 742.80m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

ValiRx (VAL) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 150,000 0.20p Suspected BUY Trade
 16:35:25 - 27-May-26
Buy* 5,000,000 0.2025p Suspected BUY Trade
 16:28:04 - 27-May-26
Buy* 5,000,000 0.2025p Suspected BUY Trade
 16:28:04 - 27-May-26
Buy* 524,654 0.1968p Ordinary
 16:25:39 - 27-May-26
Buy* 1,012,728 0.1968p Ordinary
 16:23:03 - 27-May-26
Unknown* 10,000,000 0.195p Ordinary
 16:19:08 - 27-May-26
Unknown* 10,000,000 0.2025p Ordinary
 16:18:52 - 27-May-26
Buy* 19,525 0.20p Ordinary
 15:58:07 - 27-May-26
Buy* 504,086 0.197p Ordinary
 15:41:40 - 27-May-26
Buy* 300,000 0.1977p Ordinary
 15:24:42 - 27-May-26
See more ValiRx trades

ValiRx (VAL) Share Price History

Time period:
to
Date Open High Low Close Volume
27th May 2026 (Wed) 0.195 0.20 0.20 0.20 61,515,762
26th May 2026 (Tue) 0.195 0.195 0.195 0.195 6,161,493
25th May 2026 (Mon) 0.195 0.195 0.195 0.195 0
22nd May 2026 (Fri) 0.195 0.195 0.195 0.195 24,091,695
21st May 2026 (Thu) 0.19 0.20 0.195 0.195 82,364,523
20th May 2026 (Wed) 0.19 0.19 0.19 0.19 2,190,734
19th May 2026 (Tue) 0.195 0.195 0.19 0.19 7,983,312
18th May 2026 (Mon) 0.20 0.205 0.195 0.195 7,251,415
15th May 2026 (Fri) 0.215 0.215 0.20 0.20 51,898,825
14th May 2026 (Thu) 0.27 0.241 0.241 0.241 22,845,447
13th May 2026 (Wed) 0.28 0.28 0.27 0.27 4,788,559
12th May 2026 (Tue) 0.28 0.28 0.28 0.28 2,128,266
11th May 2026 (Mon) 0.265 0.265 0.265 0.265 13,367,733
8th May 2026 (Fri) 0.265 0.265 0.265 0.265 1,510,080
7th May 2026 (Thu) 0.265 0.265 0.25 0.265 934,129
6th May 2026 (Wed) 0.265 0.265 0.265 0.265 2,202,256
5th May 2026 (Tue) 0.28 0.28 0.26 0.265 6,503,414
4th May 2026 (Mon) 0.28 0.28 0.28 0.28 0
1st May 2026 (Fri) 0.28 0.28 0.28 0.28 1,092,758
30th Apr 2026 (Thu) 0.28 0.28 0.28 0.28 13,122
29th Apr 2026 (Wed) 0.28 0.28 0.28 0.28 448,306
28th Apr 2026 (Tue) 0.28 0.28 0.28 0.28 7,638
See more ValiRx price history

ValiRx (VAL) Regulatory News

Date Source Headline
27th May 2026 7:00 am RNS Cytolytix Patent Granted
21st May 2026 7:00 am RNS Result of Oversubscribed WRAP Retail Offer
18th May 2026 7:00 am RNS WRAP Retail Offer for up to £150,000
15th May 2026 7:00 am RNS Fundraising of up to £1,155,000
31st Mar 2026 10:15 am RNS Change of Registered Office
26th Mar 2026 7:00 am RNS ValiRx Commercial Update Q1 2026
24th Mar 2026 7:00 am RNS ValiRx and TwinEdge to present Digital Twin data
4th Mar 2026 7:00 am RNS Director/PDMR Shareholding
2nd Mar 2026 7:00 am RNS ValiRx forms ValiRx Animal Health Ltd subsidiary
19th Jan 2026 7:00 am RNS Exercise of Warrants
See more ValiRx regulatory news

ValiRx (VAL) Share News

IN BRIEF: ValiRx subsidiary Cytolytix granted "core" European patent

27th May 2026 20:36

ValiRx PLC - London-based life science company - Majority-owned subsidiary Cytolytix Ltd has its European patent "Nanoparticle for Anti-Cancer Peptides and Uses Thereof" granted. Notes the patent forms a "key part" of Cytolytix's intellectual property portfolio. Says the grant of the patent boosts Cytolytix's IP position, and affirms investment in the platform developed over the last few years. Adds that it also strengthens the firm's ability to attract external investment and expands licensing and partnership opportunities. Read More

TRADING UPDATES: IAG launches new buyback; Forgent settles legal case

15th May 2026 18:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach

15th May 2026 11:49

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday. Read More

WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down

14th May 2026 10:58

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More

IN BRIEF: ValiRx establishes veterinary oncology-focused subsidiary

3rd Mar 2026 04:05

ValiRx PLC - London-based life science company - Establishes wholly owned subsidiary ValiRx Animal Health Ltd to develop and commercialise its oncology assets in the veterinary market. The subsidiary will use preclinical work from ValiRx human programmes to pursue comparative oncology opportunities. "There is a strong scientific rationale, as well as market opportunities, for this ethical approach and several examples of companies that have followed this route," says Chief Executive Officer Mark Eccleston, who adds that the three key areas of focus will be Osteosarcoma, Lymphoma and Hemangiosarcoma. ValiRx said specialist veterinary venture capitalist funds have been identified and approached with the intention that the subsidiary will be independently funded. The global veterinary oncology market was valued at USD1.58 billion in 2024 and is projected to reach USD4.86 billion by 2034, representing a compound annual growth rate of 12%. Read More

See more ValiRx news
FTSE 100 Latest
Value10,505.01
Change13.62

Login to your account

Forgot Password?

Not Registered